Recursion Pharmaceuticals, Inc.RXRXNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
2.28%
↑ 119% above average
Average (22q)
-11.86%
Historical baseline
Range
High:13.82%
Low:-86.84%
Volatility
-848.7%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 2.28% |
| Q2 2025 | 7.91% |
| Q1 2025 | -4.14% |
| Q4 2024 | -86.84% |
| Q3 2024 | 2.18% |
| Q2 2024 | -4.36% |
| Q1 2024 | 2.62% |
| Q4 2023 | 0.62% |
| Q3 2023 | -21.83% |
| Q2 2023 | -16.96% |
| Q1 2023 | -14.57% |
| Q4 2022 | 2.54% |
| Q3 2022 | 5.47% |
| Q2 2022 | -18.24% |
| Q1 2022 | 13.82% |
| Q4 2021 | -39.99% |
| Q3 2021 | -13.37% |
| Q2 2021 | -34.26% |
| Q1 2021 | -19.17% |
| Q4 2020 | -13.82% |
| Q3 2020 | -23.37% |
| Q2 2020 | 0.69% |
| Q1 2020 | 0.00% |